Crossmark

Optimal duration of adjuvant trastuzumab in treatment of early breast cancer: a meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1007/s10549-018-4967-8

Published Online: 2018-09-20

Published Print: 2019-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Niraula, Saroj http://orcid.org/0000-0002-0481-2634
Gyawali, Bishal
License Information

Text and Data Mining valid from 2018-09-20
More Information

Article History

Received: 31 July 2018

Accepted: 8 September 2018

First Online: 20 September 2018

Compliance with ethical standards

:

: Institutional research grant from Pfizer (SN). Neither of the authors have personal conflict of interest.